I just saw that Alterity Therapeutics received FDA fast track designation for their drug aimed at MSA, which is a huge step for them. With positive study results and potential applications for Parkinson’s disease, I believe this stock is poised for significant growth in the near future.

I just bought into ATHE after their encouraging Phase 2 trial results for ATH434. With the potential for FDA approval, I see a strong upside, expecting the stock to rise above $100 in the near term.